Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU’s New Cybersecurity Guidelines: Not Perfect, But Key Signposting For All Involved

Executive Summary

How do the EU’s new cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?

You may also be interested in...



Medical Devices Excluded From EU Cyber Resilience Act Proposals

Medtech companies will avoid the need to comply with yet another EU regulation, it seems, after the European Commission confirmed that proposals to tighten up cybersecurity rules for internet-connected products will not apply to medical devices.

EU MDR and IVDR Cybersecurity Measures Not Enough To Prevent Attacks, Warns ENISA

An expert from the European Union Agency for Cybersecurity (ENISA) has told Medtech Insight that although the new EU Medical Device and IVD Regulations will push developers to make more secure products, regulation is not enough to prevent cyberattacks on devices and digital health systems.

Case For EU Software Guidance Rethink Grows As Lawyers Make Their Case

Lawyers Vladimir Murovec and Annabelle Bruyndonckx from Simmons & Simmons explain why the European Commission’s recently published software guidance falls short of what the EU medtech industry needs. They describe it as an afterthought and lacking legal review compared to previous MDCG guidelines.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT126307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel